- Home
- HRMY vs GLPG Comparison
HRMY vs GLPG Comparison
Compare HRMY & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- GLPG
- Stock Information
- Founded
- HRMY 2017
- GLPG 1999
- Country
- HRMY United States
- GLPG Belgium
- Employees
- HRMY N/A
- GLPG N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- HRMY Health Care
- GLPG Health Care
- Exchange
- HRMY Nasdaq
- GLPG Nasdaq
- Market Cap
- HRMY 1.8B
- GLPG 1.9B
- IPO Year
- HRMY 2020
- GLPG 2005
- Fundamental
- Price
- HRMY $34.00
- GLPG $30.32
- Analyst Decision
- HRMY Strong Buy
- GLPG Sell
- Analyst Count
- HRMY 9
- GLPG 4
- Target Price
- HRMY $54.44
- GLPG $25.33
- AVG Volume (30 Days)
- HRMY 642.5K
- GLPG 239.4K
- Earning Date
- HRMY 08-05-2025
- GLPG 07-23-2025
- Dividend Yield
- HRMY N/A
- GLPG N/A
- EPS Growth
- HRMY 13.13
- GLPG N/A
- EPS
- HRMY 2.62
- GLPG N/A
- Revenue
- HRMY $744,852,000.00
- GLPG $311,493,731.00
- Revenue This Year
- HRMY $20.10
- GLPG $0.78
- Revenue Next Year
- HRMY $18.01
- GLPG N/A
- P/E Ratio
- HRMY $13.10
- GLPG N/A
- Revenue Growth
- HRMY 20.62
- GLPG 18.32
- 52 Week Low
- HRMY $26.47
- GLPG $22.36
- 52 Week High
- HRMY $41.61
- GLPG $31.23
- Technical
- Relative Strength Index (RSI)
- HRMY 58.91
- GLPG 67.62
- Support Level
- HRMY $31.70
- GLPG $28.21
- Resistance Level
- HRMY $35.08
- GLPG $30.64
- Average True Range (ATR)
- HRMY 0.95
- GLPG 0.52
- MACD
- HRMY 0.27
- GLPG 0.23
- Stochastic Oscillator
- HRMY 71.80
- GLPG 91.29
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.